Lecia Bushak is a Senior Reporter at MM+M (Medical Marketing & Media), where she covers health care topics. With a background in journalism and a creative side, Lecia brings a unique perspective to her reporting. Her work has appeared in various publications, including PRWeek and Campaign US.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
This information evolves through machine learning and human feedback. Improve this profile .
Kite Pharma will build on its previous collaboration with Arcellx to pick up ACLX-001, a BCMA-targeted CAR-T cell therapy for multiple myeloma.
The Extra Life campaign takes inspiration from 1990s video games, showcasing how high school and college students can inject positivity into their day by donating blood.
If Propella's PRL-02 proves to be effective and wins approval, it would provide Astellas with yet another contender against Zytiga, which once brought in nearly $2 billion in revenue for Johnson & Johnson.
The House Committee on Veterans’ Affairs’ Subcommittee on Health held what appears to be its first official hearing on the use of psychedelic therapies for veterans’ mental health care.
From using Tic Tac containers to travel with pills, to finding “tricks” to make pills “kick in faster,” #MedicationHack on TikTok is riddled with questionable suggestions.
Caraway Therapeutics brings three preclinical programs in Parkinson's and rare disease to Merck, which is putting down $610 million total for the deal.
The FDA announced the launch of a pilot program, dubbed START, to address challenges associated with rare disease development and speed up the regulatory process.
Latin America-based Botanical Solutions is banking on its platform that sustainably produces QS-21, a compound from the Quillaja saponaria tree that's used in vaccine adjuvants.
Latin America-based Botanical Solutions is banking on its platform that sustainably produces QS-21, a compound from the Quillaja saponaria tree that’s used in vaccine adjuvants.
China says uptick in respiratory illnesses is caused by flu and known pathogens, not a novel virus; Xenon Pharmaceuticals' experimental major depressive disorder drug fails in Phase 2 trial; AbbVie, Genmab announce the FDA granted breakthrough therapy designation to their epcoritamab treatment.
(833) 317-6278 
